Analyses of human vaccine-specific circulating and bone marrow-resident B cell populations reveal benefit of delayed vaccine booster dosing with blood-stage malaria antigens

Analyses of human vaccine-specific circulating and bone marrow-resident B cell populations reveal benefit of delayed vaccine booster dosing with blood-stage malaria antigens

We have previously reported primary endpoints of a clinical trial testing two vaccine platforms for the delivery of Plasmodium vivax malaria DBPRII: viral vectors (ChAd63, MVA), and protein/adjuvant (PvDBPII with 50µg Matrix-M™ adjuvant). Delayed boosting was necessitated due to trial halts during t...

Full description

Bibliographic Details
Main Authors: Jordan R. Barrett, Sarah E. Silk, Catherine G. Mkindi, Karolina M. Kwiatkowska, Mimi M. Hou, Amelia M. Lias, Wilmina F. Kalinga, Ivanny M. Mtaka, Kirsty McHugh, Martino Bardelli, Hannah Davies, Lloyd D. W. King, Nick J. Edwards, Virander S. Chauhan, Paushali Mukherjee, Stella Rwezaula, Chetan E. Chitnis, Ally I. Olotu, Angela M. Minassian, Simon J. Draper, Carolyn M. Nielsen
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Immunology
Subjects:
B cells
vaccine dosing regimen
malaria
memory B cells
plasma cells
bone marrow
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1193079/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1193079/full

Similar Items